Zumutor – Licensing Opportunity for Next Generation Tumor-Directed Immunotherapeutics Harnessing the Power of NK Cells
Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification
Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)
Partnering/Licensing Opportunity for Tecarfarin, a Phase 3-Ready Oral Anticoagulant for Patients with Certain Orphan Diseases
